Cell and Gene Therapy (CGT) represents a transformative area of modern medicine that seeks to modify or engineer living cells in order to treat, control, or potentially cure complex diseases. It has the potential to revolutionise medicine by offering long-term and possibly curative treatment options for a variety of illnesses, including the dreaded malignancies, genetic disorders, autoimmune diseases, and many more.
Within CGT, two rapidly advancing therapeutic strategies are Chimeric Antigen Receptor T-cell (CAR-T) therapy and Chimeric Antigen Receptor Natural Killer cell (CAR-NK) therapy.
CAR-T therapy involves collecting a patient’s own T cells and genetically engineering them to express a synthetic receptor known as a Chimeric Antigen Receptor (CAR). This receptor enables T cells to recognise and selectively destroy cancer cells. Following modification, the cells are expanded and reinfused into the patient to mount a precise immune attack. CAR-T therapies have demonstrated remarkable efficacy, particularly in several forms of blood cancers, and continue to evolve for broader applications across oncology and potentially autoimmune diseases.
We offer comprehensive CAR-T therapy development capabilities, leveraging deep expertise in genetic engineering, scalable process development, and commercialisation frameworks. Our strong command of viral vector technologies and quality management systems enables efficient and compliant progression from proof-of-concept to clinical translation. With a focus on advancing CAR-T applications beyond haematologic malignancies, we support biopharmaceutical partners in optimising their products, resolving technical challenges, and accelerating innovation across the CAR-T development lifecycle.
CAR-NK therapy leverages Natural Killer (NK) cells, which form a critical part of the innate immune system and naturally target abnormal or infected cells. By equipping NK cells with CARs, their recognition and killing of cancer cells is significantly enhanced. CAR-NK approaches offer potential advantages, including reduced risk of severe immune-related toxicities and the possibility of using donor-derived “off-the-shelf” NK cells. These attributes position CAR-NK therapies as an exciting next wave in cellular immunotherapy for cancers and beyond.
We provide integrated CAR-NK therapy development capabilities, combining expertise in NK cell biology, CAR construct engineering, and scalable donor-derived manufacturing approaches. Our domain knowledge supports efficient progression from proof-of-concept through clinical translation, strengthened by robust process optimisation and quality management systems. With a focus on safe, potent, and potentially off-the-shelf cellular immunotherapies, we partner with biopharmaceutical organisations to enhance innovation, overcome technical barriers, and accelerate next-generation CAR-NK solutions for cancer and emerging disease areas.
Bacterial and Viral vaccines technologies Recombinant & conjugate Polysaccharide vaccines technologies Invigorate Bio wants to use platform technologies to develop a variety of vaccines, including the Pneumococcal conjugate vaccine (20 valent), Hib-TT conjugate vaccine, Meningococcal conjugate vaccine, Hepatitis B vaccine, rTyphoid, Dengue, JE, mRNA vaccine, influenza vaccine, etc. to support India’s One Health mission and make healthcare accessible to everyone.
Platform technologies facilitate the production of products in greater quantities and at lower costs than traditional approaches. To maintain our livestock healthy and productive, Invigorate Bio is keenly interested in developing a portfolio of veterinary and poultry vaccines (again, to mention a few: FMD, rAnthrax, Brucella, Rabies, PPR, Fowl pox, New Castle disease, and Marek’s disease).
With platform technologies, Invigorate Bio has deep knowledge and competence in research, process development, and commercial scale production of several vaccines, such as the 20-valent pneumococcal conjugate vaccine, the Hib-TT conjugate vaccine, the meningococcal conjugate vaccine, and the hepatitis B vaccine.
About 85% of the enzymes used in the diagnostics sector are imported into India. Aiming to create recombinant enzymes such creatinase, creatininase, sarcosine oxydase, uricase FAD dependent glucose dehydrogenase, etc. for the diagnostics business, Invigorate sees a significant chance to make the nation self-sufficient in this area.
These enzymes are mostly employed in the testing of lipid metabolism, liver function, pancreatic function, kidney function, and diabetes.
Utilising platform technologies, Invigorate Bio has extensive knowledge and competence in the development of recombinant enzymes.
Invigorate Biotechnologies LLP Punjab Biotechnology Incubator (PBTI) Department of Science, Technology & Environment Knowledge City, Sector – 81, SAS Nagar Mohali- 140308
© Copyright 2026. All rights reserved. Website Designed by Triple D Studio
